- Research article
- Open Access
- Open Peer Review
Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways
BMC Cancer volume 17, Article number: 486 (2017)
Mounting evidence has showed that Tumor-associated calcium signal transducer 2 (Trop2) is upregulated in various kinds of human cancers and plays important roles in tumorigenesis. However, the expression status and functional significance of Trop2 in thyroid cancer are largely unknown.
We first determined the expression of Trop2 by using RNAseqV2 data sets for thyroid cancer deposited on The Cancer Genome Atlas (TCGA) website. The expression of Trop2 was then confirmed by real-time reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry assays. Cell invasion and migration were assessed by conducting Transwell and wound healing assays. Furthermore, we explored the underlying mechanisms by using real-time RT-PCR, Western blot, zymography, and luciferase reporter assays.
In this study, we demonstrated that the expression of Trop2 was significantly elevated in thyroid cancer and that its expression level was correlated with the tumor-node-metastasis (TNM) staging and N classification. Dysregulation of Trop2 altered the invasive capability of thyroid cancer cells. Further mechanistic study revealed that MMP2 expression was upregulated by Trop2. Moreover, we found that the effects of Trop2 were dependent on ERK and JNK pathways. The results from clinical specimens showed that Trop2 expression correlated with MMP2 expression in primary thyroid cancer.
The current study suggests that elevated expression of Trop2 may represent an important molecular hallmark that is biologically and clinically relevant to the progression of thyroid cancer.
The incidence of thyroid cancer, the most common endocrine malignancy, continues to increase steadily during the past few decades worldwide [1, 2]. The majority of thyroid cancer types are classified as: follicular epithelial cell-derived papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), anaplastic thyroid cancer (ATC), and para-follicular C-cell derived medullary thyroid cancer (MTC) . The prognosis of patients with thyroid cancer is closely correlated with local invasion outside the thyroid capsule and the development of distant metastases . Therefore, dissecting the molecular mechanisms underlying thyroid cancer invasion and metastasis is still imperative and may put new insight into the clinical treatment of thyroid cancer.
Human tumor-associated calcium signal transducer 2 (TACSTD2), also known as trophoblast cell-surface antigen 2 (Trop2), is a type I transmembrane glycoprotein originally identified in human placental trophoblastic tissue . As a cell surface receptor, it can recognize specific ligands  and increase the level of intracellular calcium . Although the biological function of Trop2 is unclear, accumulating evidence has demonstrated that its expression is elevated in various malignant tissues, whereas in human normal tissues relatively low or no Trop2 expression is observed [8,9,10,11]. Over-expression of Trop2 has been implicated to correlate with poor prognosis of patients with several kinds of cancers [12, 13]. Immunohistochemistry (IHC) was performed in 94 PTC specimens and results showed that Trop2 was over-expressed in PTC . However, the expression of Trop2 has not been characterized in FTC and ATC. Moreover, the clinical and functional significance of Trop2 in thyroid cancer remains unclear.
MAPK (mitogen-activated protein kinase) signaling pathway is a highly conserved intracellular pathway that plays vital roles in transmission of signals to cell nucleus, where they transcriptionally regulate genes that are involved in various cellular processes [15, 16]. The fundamental role of MAPK signaling pathway has been well demonstrated in human tumorigenesis, particularly for PTC . Recent studies, which focused on investigating the molecular background of thyroid cancer, have shown that inappropriate activation of MAPK is a vital intracellular regulator for thyroid tumorigenesis . The aberrant activation of MAPK pathway in thyroid cancer is driven by some genetic alterations, including BRAF, RAS, RET-PTC, and ALK mutations [19,20,21,22] . To fully understand the regulation of MAPK signaling in thyroid cancer is biologically as well as clinically important for future development of treatment strategies.
In the current study, we aimed at investigating the role of Trop2 in the development and progression of thyroid cancer. We evaluated the pro-invasive effect of Trop2 in thyroid cancer and explored the possible underlying mechanisms.
Cell lines and reagents
The K1 (papillary cancer), FTC-133 (follicular cancer), and 8505C (anaplastic cancer) thyroid cancer cell lines were from the European Collection of Cell Cultures (ECACC, Salisbury, United Kingdom). Cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Life Technology, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS, Gibco, Grand Island, NY) in a humidified cell culture incubator at 37 °C and 5% CO2 . PD98059 (ERK1/2 inhibitor), SP600125 (JNK inhibitor), and SB203580 (p38 inhibitor) were purchased from Cell Signaling Technology (Beverly, MA).
Patients and tissue specimens
This study was conducted on a total of 96 cases of paraffin embedded thyroid carcinomas (67 cases of PTC, 20 cases of FTC, and 9 cases of ATC), 13 cases of goiters, and 15 cases of adenoma samples, which had been clinically and histologically diagnosed at the First Affiliated Hospital of Sun Yat-sen University between 2010 to 2015. Eighteen freshly collected thyroid cancer specimens and the matched adjacent non-cancerous thyroid tissues were collected, frozen, and stored in liquid nitrogen until assayed. Informed consent from patients and ethics approval from the Institutional Research Ethics Committee was obtained.
Immunohistochemistry (IHC) analysis was performed to study altered protein expression in formalin-fixed and paraffin-embedded human thyroid lesions. The following primary antibodies were used: anti-Trop2 (R&D Systems, Minneapolis, MN), and anti-MMP2 (Lifespan Bioscience, Seattle). The degree of immunostaining was examined and scored independently by two observers by combining both the proportion of positively staining tumor cells and the staining intensity as previously described .
Vectors and retroviral infection
Trop2 construct was generated by sub-cloning PCR-amplified full-length human Trop2 cDNA into pQCXIP (Clontech, Mountain View, CA). The Trop2-shRNA clones (TR308966) were purchased from Origene (Rockville, MD, USA). PT67 (Clontech, Mountain View, CA), an NIH 3 T3-derived packaging cell line, was purchased for retroviral transduction . The indicated plasmids were transfected into the PT67 cell respectively using Lipofectamine 3000 (Invitrogen, San Diego, CA). The supernatant was harvested, passed through a 0.45 μm filter, and incubated with indicated cells together with 8 μg/mL polybrene. Stable cell lines were selected by treatment with 0.5 μg/mL puromycin for 10 days, beginning 48 h after infection.
Western blotting (WB) was performed according to a standard method as described previously . The following primary antibodies were used: anti-Trop2 (R&D Systems, Minneapolis, MN), anti-ERK1/2 and anti-phospho-ERK1/2 (Cell Signaling Technology, Beverly, MA), anti-p38, anti-phospho-p38, anti-JNK, and anti-phospho-JNK (Abcam, Cambridge, MA), and anti-α-tubulin (Sigma-Aldrich, St. Louis, MO).
RNA extraction and real-time polymerase chain reaction (PCR)
RNA extraction, RT, and real-time PCR were performed as described previously . The primers selected are as follows: MMP2 forward, 5′-CCAGCAAGTAGATGCTGCCT-3′ and reverse, 5′-GGGGTCCATTTTCTTCTTCA-3′; MMP7 forward, 5′-CACATCAGTGGGAACAGGC-3′ and reverse, 5′-GCATTTCCTTGAGGTTGTCC-3′; MMP9 forward, 5′-AGACGACATAGACGGCATCC-3′ and reverse, 5′-CTGTCGGCTGTGGTTCAGT-3′; MMP11 forward, 5′- CCACTGACTGGAGAGGGGT-3′ and reverse, 5′- TTCACAGGGTCAAACTTCCA-3′; MMP13 forward, 5′- TGATGAAACCTGGACAAGCA-3′ and reverse, 5′- GGTCCTTGGAGTGATCCAGA-3′; and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) forward, 5′-GACTCATGACCACAGTCCATGC-3′ and reverse, 5′-AGAGGCAGGGATGATGTTCTG-3′. Data analysis was performed using the comparative Ct method and results were normalized to GAPDH. Each sample was analyzed three times in triplicate.
Cells (2 × 104) in serum-free medium were plated into the upper chamber of 8 μm pore boyden chambers coated with or without Matrigel (BD Biosystems, San Jose, CA). The lower chamber was filled with medium containing 10% FBS. After 24 h incubation, cells on the surface of upper chamber were removed by scraping with a cotton swab. Migrating and invading cells on the lower membrane surface were fixed in 4% paraformaldehyde, stained with 0.1% crystal violet and counted in 5 random fields. Each assay was replicated three times.
Wound healing assay
When indicated cells reached 90-95% confluence, they were scratched with a micropipette tip in the cell monolayer. After 24 h incubation, recovery of the wound was observed and images were captured by a phase-contrast microscope.
Gelatin zymography analysis
Enzymatic activity of MMP2 was detected using MMP Zymography Assay Kit (P1700, Applygen Technologies, Beijing, China). Briefly, supernatants of indicated cells were collected and BCA assay measure was performed to determine the protein content. Equal amount of supernatants were mixed with an equal volume of 2 × SDS-PAGE non-reducing buffer, and electrophoresed on 8% polyacrylamide gels containing 1 × substrate G. The gels were then rinsed by 1 × Buffer A twice at room temperature and then incubated in 1 × Buffer B at room temperature for 4 h. The gels were then stained with Coomassie blue R250 and then destained in destaining buffer (10% acetic acid and 20% methanol). Each assay was replicated three times.
Luciferase reporter assay
The reporter plasmid pGL2-MMP2 was purchased from Addgene (Cambridge, MA). The AP1 reporter assay kit was purchased from SABiosciences (Frederick, MD). Dual-Luciferase reporter assays were performed according to the manufacturer’s instructions (Promega, Madison, WI) and as described previously .
AP1 decoy oligodeoxynucleotide (ODN)
AP1 decoy and mutated control used were double-stranded phosphorothioate-oligonucleotides. The AP-1 decoy OND sequence was 5′-CGCTTGATGACTCAGCCGGAA-3′; the mutated control was 5′- CGCTTGATGACTTGGCCGGAA-3′. Double strands (ds) ODN were prepared by melting complementary OND at 95 °C for 5 min and subsequently at RT for 4 h .
All statistical analyses were carried out using the SPSS 13.0 statistical software package. All values represent at least three independent experiments and are expressed as the means ± SD. The differences between two experimental conditions were compared on a one-to-one basis using the Student’s t tests. Spearman rho correlation method was used to describe correlations between expression data. P < 0.05 was considered statistically significant.
Trop2 is overexpressed in thyroid cancer
To explore the expression of Trop2 in thyroid cancer, we initially investigated the expression of Trop2 in 59 pairs of thyroid tumors and their adjacent non-tumorous thyroid tissues using RNAseqV2 data sets for thyroid cancer deposited on The Cancer Genome Atlas (TCGA, https://cancergenome.nih.gov/) website. The results showed that Trop2 expression level was significantly elevated in most thyroid cancer tissues as compared with their respectively adjacent non-tumorous thyroid tissues (Fig. 1a). Next, we validated the expression of Trop2 in 18 pairs of tumors and adjacent non-tumorous tissues using qRT-PCR. As shown in Fig. 1b, in agreement with the TCGA data, the expression levels of Trop2 were significantly increased in most thyroid tumor tissues in comparison with those in adjacent non-tumorous thyroid tissues. We next investigated the clinical relevance of Trop2 in thyroid cancer, we performed IHC to analyze the expression levels of Trop2 in goiters (13 cases), adenomas (15 cases), and thyroid cancers (96 cases). As compared with benign thyroid lesions, namely, goiters and adenomas, the expression level of Trop2 was significantly upregulated in thyroid cancer tissues (Fig. 1c). Intriguingly, in most goiters (10/13) and adenoma tissues (12/15), the expression of Trop2 was low, on contrary, Trop2 is highly expressed in 53.1% of thyroid malignant lesions (51/96). Importantly, significant correlations between Trop2 expression and tumor-node-metastasis (TNM) staging (p = 0.041) or N classification (p = 0.013) were observed (Table 1). Taken together, in accordance with previous studies, these data suggest that Trop2 is upregulated and may play functional roles in thyroid cancer.
Depletion of endogenous Trop2 inhibits the invasion and migration of thyroid cancer cells
Given that it has been demonstrated that Trop2 is associated with the invasion and metastasis of several human cancers [27, 28], we next investigated the role of Trop2 in regulating thyroid cancer cell invasion and migration. To this end, we silenced endogenous Trop2 by specific short hairpin (shRNA) in K1 and 8505C cells. The effect of knockdown was confirmed by performing WB analyses (Fig. 2a). We next investigated whether knockdown of Trop2 plays roles in cell invasion and migration. Results of Transwell invasion (coated with Matrigel) and migration (without Matrigel) assays showed that knockdown of endogenous Trop2 suppressed the invasiveness and migration of K1 and 8505C cells as compared with control cells (Fig. 2b-e). Furthermore, migration capabilities of indicated cells were assessed by wound healing assay. As shown in Fig. 2f, depletion of Trop2 expression in thyroid cancer resulted in retarded wound closing when compared with the vector control cells. Taken together, these results suggest that silencing of the Trop2 inhibits the invasiveness and migration capability of thyroid cancer cells.
Ectopic over-expression of Trop2 promotes the invasion and migration of thyroid cancer cells
In order to further investigate the role of Trop2 in thyroid cancer cell invasion and migration, Trop2 was stably transduced into FTC-133 cells, in which the expression of Trop2 cannot be detected (Fig. 3a). As shown in Fig. 3, b and c, Matrigel-coated or uncoated Transwell assays indicated that Trop2 over-expression significantly enhanced the ability of invasiveness and migration of thyroid cancer cells. In addition, wound healing assay showed that over-expression of Trop2 promoted the migratory speed of FTC-133 cells as compared with vector control cells (Fig. 3d). These data, together with the results from Fig. 2, indicate that Trop2 is involved in the invasion and migration of thyroid cancer cells.
Trop2 regulates the expression of MMP2
It has been well demonstrated that matrix metalloproteinases (MMPs) play important role in tumor progression. Many MMP family members, such as MMP2, MMP7, MMP9, MMP11, and MMP13, have been implicated to be associated with the development and progression of thyroid cancer . In light of these, we therefore investigated whether MMPs were involved in the effects of Trop2 on thyroid cancer cell invasion. As shown in Fig. 4a, only mRNA level of MMP2, not MMP7, MMP9, MMP11 or MMP13, was suppressed by Trop2 depletion. Promoter assay showed that knockdown of Trop2 decreased the luciferase activity of MMP2 promoter in K1 and 8505C cells (Fig. 4b). To further confirm the role of Trop2 in thyroid cancer, we evaluated the effects of over-expressing Trop2 on the MMP2 expression in FTC-133 cells. As expected, ectopic over-expression of Trop2 significantly promoted the expression and promoter activity of MMP2 in FTC-133 cells (Fig. 4c and d). Moreover, zymography were performed to test the MMP2 enzymatic activity in Trop2 dysregulated thyroid cancer cells. As shown in Fig. 4e and f, knockdown of Trop2 in K1 and 8505 cells reduced the MMP2 activity, whereas, overexpression of Trop2 in FTC-133 cells resulted in increased activity of MMP2. Collectively, our data suggest that the role of Trop2 on thyroid cancer cell invasion and migration was mediated by regulation of MMP2.
AP1 mediates the regulatory role of Trop2 on MMP2 expression
To investigate the signaling pathway that controls the expression of MMP2 in response to alteration of Trop2 expression, the activation status of transcription factor AP1, a well-known regulator of MMP2, was evaluated in thyroid cancer cells with Trop2 overexpression or knockdown. To this end, we first examined whether dysregulated expression of Trop2 has an effect on AP1 transcriptional activity. As shown in Fig. 5a and b, the luciferase activity of AP1 reporter was decreased by depletion of Trop2 and increased when Trop2 was overexpressed, suggesting a potential role of AP1 in the signaling cascade that mediates the regulatory role of Trop2 on MMP2 expression. To further confirm the critical role of AP1 in this course, AP1 decoy phosphorothioated double-stranded ONDs were used. As indicated in Fig. 5c, the Trop2-stimulated MMP2 mRNA expression was suppressed by the decoy of AP1. Consistently, AP1 decoy also lead to inhibition of Trop2-induced MMP2 promoter reporter activity (Fig. 5d). Together, these data indicate that AP1 is critically required for Trop2-regulated MMP2 expression.
Trop2 regulates MMP2 expression by modulating ERK and JNK signaling
Next, we delineated how Trop2 regulates the activity of AP1. As shown in Fig. 5e, the phosphorylation levels of ERK1/2 and JNK were significantly decreased in Trop2-knocked down thyroid cancer cells as compared with vector control cells, and increased phosphorylation of ERK1/2 and JNK was observed in Trop2-transduced cells. However, the phosphorylation of p38 did not change when the expression of Trop2 was deregulated (Fig. 5e). To further confirm the role of MAPK pathway in Trop2-induced MMP2 expression, the MAPKs inhibitors, namely PD98059 (ERK1/2 inhibitor), SP600125 (JNK inhibitor), and SB203580 (p38 inhibitor) were used. Among these inhibitors, only PD98059 and SP600125 could suppress Trop2-induced MMP2 expression, suggesting that ERK1/2 and JNK play a critical role in Trop2-regulated MMP2 expression (Fig. 5f). Moreover, Trop2-induced activation of AP1 was significantly inhibited by treatment with PD98059 or SP600125 (Fig. 5g). Taken together, these results suggest that MAPK ERK and JNK signaling are involved in the regulatory roles of Trop2 on AP1 activation and MMP2 expression.
Trop2 expression correlates with MMP2 expression in primary thyroid cancer
We next investigate whether there is an association between the expression levels of Trop2 and MMP2 in the clinical specimens. As shown in Fig. 6a and b, 62.7% (32 cases) of thyroid cancer samples with high Trop2 expression (51 cases) exhibited high levels of MMP2, whereas 64.4% (29 cases) of samples with low Trop2 expression (45 cases) showed low levels of MMP2 (p < 0.05) (Spearman rho = 0.276, P = 0.007). Furthermore, we used RNAseqV2 data mined from TCGA and sorted the patient cohort into the top and bottom quartiles of Trop2 expression (Trop2 high and low, n = 126 respectively) (Spearman rho = 0.300, P < 0.001). As shown in Fig. 6c, 67.5% (85 cases) of samples with low Trop2 expression exhibited low levels of MMP2 (less than the median), whereas 32.5% (41 cases) of samples with high Trop2 expression showed low levels of MMP2, suggesting that Trop2 expression significantly correlated (P < 0.05) the level of MMP2 in thyroid cancer. These findings are consistent with Trop2 functioning as a regulator of MMP2 expression.
As an oncogene, Trop2 has been found to be up-regulated in various kinds of human cancers, including glioma, breast cancer, cervical cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and prostate cancer [9, 30,31,32]. In line with previous studies , the results of current study showed that the expression of Trop2 is overexpressed in clinical thyroid cancer specimens. Notably, the expression of Trop2 is correlated with TNM staging and N classification of thyroid cancer. These data put new insights into the molecular alterations that are involved in the thyroid tumorigenesis. Further studies are needed to clarify the mechanisms underlying the overexpression of Trop2 in thyroid cancer, which will enhance our understanding of the pathogenesis of thyroid malignancy.
Previous studies about the biological roles of Trop2 in cancers were mainly focused on the pro-proliferative effect of Trop2 in human cancers [31,32,33]. Nevertheless, a few studies have assessed the pro-invasive role of Trop2 in tumorigenesis [12, 34]. Consistent with these studies, our data showed that the invasion and migration ability of thyroid cancer was inhibited by depletion of Trop2 expression and promoted when Trop2 was over-expressed, suggesting a requirement of Trop2 in thyroid cancer invasion and migration.
Accumulating evidence indicate that MMPs play important roles in tumor development and progression . Given that ECM is the first vital barrier in the tumor invasion and metastasis process and the main component of ECM is type IV collagen, together with important role of MMP2 in degradation of type IV collagen, MMP2 is regarded as a key enzyme involved in invasion and metastasis of cancer . Trop2 seems to be critical in regulating MMP2 expression in our study because our data revealed upregulation of MMP2 mRNA level and activation of MMP2 promoter reporter in Trop2-overexpressing thyroid cancer cells, as well as down-regulation of MMP2 mRNA and inactivation of MMP2 promoter reporter in Trop2 knocked down thyroid cancer cells. The results of our current study using AP1 decoy ODNs confirmed that activation of AP1 was attributable to regulation of MMP2. Therefore, data obtained from the present study suggest that AP1 may play a role in mediating the regulation of MMP2 by Trop2.
In current study, we showed that expression of Trop2 in thyroid cancer has effect on MAPK activation. These results provide new insights into the complex regulatory mechanism for activation of MAPK in thyroid cancer. Nevertheless, mechanism by which Trop2 activates MAPK in thyroid cancer cells remains to be determined.
In summary, we show that Trop2 is overexpressed in thyroid cancer and promotes the invasion and migration of thyroid cancer cells via MAPK ERK/JNK/AP1/MMP2 signaling, potentially offering new molecular targets for treatment of thyroid cancer.
Anaplastic thyroid cancer
Follicular thyroid cancer
Mitogen-activated protein kinase
Papillary thyroid cancer
Real-time reverse transcription-polymerase chain reaction.
The Cancer Genome Atlas
Tumor-associated calcium signal transducer 2
Vaccarella S, Dal Maso L, Laversanne M, Bray F, Plummer M, Franceschi S. The impact of diagnostic changes on the rise in thyroid cancer incidence: a population-based study in selected high-resource countries. Thyroid. 2015;25(10):1127–36.
Luster M, Weber T, Verburg FA. Differentiated thyroid cancer-personalized therapies to prevent overtreatment. Nat Rev Endocrinol. 2014;10(9):563–74.
Brown RL, de Souza JA, Cohen EE. Thyroid cancer: burden of illness and management of disease. J Cancer. 2011;2:193–9.
Nilubol N, Boufraqech M, Zhang L, Kebebew E. Loss of CPSF2 expression is associated with increased thyroid cancer cellular invasion and cancer stem cell population, and more aggressive disease. J Clin Endocrinol Metab. 2014;99(7):E1173–82.
Lipinski M, Parks DR, Rouse RV, Herzenberg LA. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci U S A. 1981;78(8):5147–50.
Lin JC, Wu YY, Wu JY, Lin TC, Wu CT, Chang YL, Jou YS, Hong TM, Yang PC. TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. EMBO Mol Med. 2012;4(6):472–85.
Ripani E, Sacchetti A, Corda D, Alberti S. Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer. 1998;76(5):671–6.
Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi AL, Bonasera V, Lattanzio R, de Lange R, Weidle UH, Piantelli M, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32(2):222–33.
Varughese J, Cocco E, Bellone S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, et al. Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Am J Obstet Gynecol. 2011;205(o):567 e1–7.
Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, Ravaggi A, Bandiera E, Romani C, Zanotti L, et al. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer. 2010;46(5):944–53.
Chen R, Lu M, Wang J, Zhang D, Lin H, Zhu H, Zhang W, Xiong L, Ma J, Mao Y, et al. Increased expression of Trop2 correlates with poor survival in extranodal NK/T cell lymphoma, nasal type. Virchows Arch. 2013;463(5):713–9.
Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, Gastl G, Spizzo G. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008;99(8):1290–5.
Liu T, Liu Y, Bao X, Tian J, Liu Y, Yang X. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PLoS One. 2013;8(9):e75864.
Addati T, Achille G, Centrone M, Petroni S, Popescu O, Russo S, Grammatica L, Simone G. TROP-2 expression in papillary thyroid cancer: a preliminary cyto-histological study. Cytopathology. 2015;26(5):303–11.
MacCorkle RA, Tan TH. Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys. 2005;43(3):451–61.
Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med. 2006;38(3):200–11.
Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006;6(4):292–306.
Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, Nikiforov YE. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest. 2005;115(1):94–101.
Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184–99.
Karga H, Lee JK, Vickery AL Jr, Thor A, Gaz RD, Jameson JL. Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab. 1991;73(4):832–6.
Santoro M, Melillo RM, Fusco A. RET/PTC activation in papillary thyroid carcinoma: European journal of endocrinology prize lecture. Eur J Endocrinol. 2006;155(5):645–53.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.
Guan H, Liang W, Liu J, Wei G, Li H, Xiu L, Xiao H, Li Y. Transmembrane protease serine 4 promotes thyroid cancer proliferation via CREB phosphorylation. Thyroid. 2015;25(1):85–94.
Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res. 2005;65(12):5153–62.
Liang W, Guan H, He X, Ke W, Xu L, Liu L, Xiao H, Li Y. Down-regulation of SOSTDC1 promotes thyroid cancer cell proliferation via regulating cyclin A2 and cyclin E2. Oncotarget. 2015;6(31):31780.
Viedt C, Dechend R, Fei J, Hansch GM, Kreuzer J, Orth SR. MCP-1 induces inflammatory activation of human tubular epithelial cells: involvement of the transcription factors, nuclear factor-kappaB and activating protein-1. J Am Soc Nephrol. 2002;13(6):1534–47.
Trerotola M, Jernigan DL, Liu Q, Siddiqui J, Fatatis A, Languino LR. Trop-2 promotes prostate cancer metastasis by modulating beta(1) integrin functions. Cancer Res. 2013;73(10):3155–67.
Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, Zhang MF, Wan DS. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Color Dis. 2009;24(8):875–84.
Kalhori V, Tornquist K. MMP2 and MMP9 participate in S1P-induced invasion of follicular ML-1 thyroid cancer cells. Mol Cell Endocrinol. 2015;404:113–22.
Stepan LP, Trueblood ES, Hale K, Babcook J, Borges L, Sutherland CL. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem. 2011;59(7):701–10.
Guerra E, Trerotola M, Aloisi AL, Tripaldi R, Vacca G, La Sorda R, Lattanzio R, Piantelli M, Alberti S. The Trop-2 signalling network in cancer growth. Oncogene. 2013;32(12):1594–600.
Ning S, Liang N, Liu B, Chen X, Pang Q, Xin T. TROP2 expression and its correlation with tumor proliferation and angiogenesis in human gliomas. Neurol Sci. 2013;34(10):1745–50.
Lin H, Zhang H, Wang J, Lu M, Zheng F, Wang C, Tang X, Xu N, Chen R, Zhang D, et al. A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo. Int J Cancer. 2014;134(5):1239–49.
Wang XD, Wang Q, Chen XL, Huang JF, Yin Y, Da P, Wu H. Trop2 inhibition suppresses the proliferation and invasion of laryngeal carcinoma cells via the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway. Mol Med Rep. 2015;12(1):865–70.
Tauro M, McGuire J, Lynch CC. New approaches to selectively target cancer-associated matrix metalloproteinase activity. Cancer Metastasis Rev. 2014;33(4):1043–57.
Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 2003;200(4):448–64.
This research was supported by grants from the National Natural Science Foundation of China (No. 81370076, 81572623, 81572624, 81602347); and the Natural Science Foundation of Guangdong Province (No. 2016A030310169). The foundation had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Availability of data and materials
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. RNAseq data of thyroid cancer tissues were mined from The Cancer Genome Atlas (TCGA) (https://cancergenome.nih.gov/).
Ethics approval and consent to participate
The use of clinical specimens and clinical data were reviewed and approved by the Institutional Research Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University. Written informed consent was obtained from all patients who participated in the study. This study does not involve animal studies.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Guan, H., Guo, Z., Liang, W. et al. Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways. BMC Cancer 17, 486 (2017). https://doi.org/10.1186/s12885-017-3475-2
- Thyroid cancer